CONTENT

This domain states the following, "A non-inferiority, phase 3, randomized 21, open-label trial that compared the efficacy and safety of VELCADE." Our analyzers analyzed that the web site also stated " This site is intended for U." The Website also stated " Now approved VELCADER bortezomib for retreatment in relapsed multiple myeloma. ITS THE MOMENT OF TRUTH. Will you tell your patients with previously untreated multiple myeloma that 1year. 50 weeks median of VELCADE. For future news and information." The website's header had velcade for healthcare professionals as the most important search term. It was followed by bortezomib for healthcare professionals, bortezomib prescribing information, and velcade prescribing information which isn't as highly ranked as velcade for healthcare professionals. The next words they uses is velcade hcp. velcade pi was also included and might not be understood by search engines.